Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

Emerg Microbes Infect. 2024 Dec;13(1):2332680. doi: 10.1080/22221751.2024.2332680. Epub 2024 Apr 3.

Abstract

After the use of facemasks, other isolation measures enacted during the SARS-CoV-2 pandemic were lifted, respiratory pathogens, such as RSV, reappeared, but until the November 2023 WHO alert for China, M. pneumoniae had virtually disappeared. After observing a similar reappearance in our hospital, a retrospective analysis of the number of positive M. pneumoniae tests. Between 2018 and December 2023, 1619 PCR tests were ordered and 43 (2.6%) of them were positive. Two outbreaks, one in 2018 and one in 2023, accounted for the majority of cases. Tests were usually ordered in an outpatient setting (53.54%, n = 23) and most of them were paediatric patients with a mean age (sd) of 10.2 (6.2) years. As for the severity of the cases, in the 2018 outbreak, of 15 children who tested positive, 53.3% (n = 8) were admitted to the ward and 6.7% (n = 1) at the intensive care unit. Whereas in 2023, 2 patients were tested in the ward (10.5%) and one in the intensive care unit (5.2%) from a total of 19 patients. The positive rate in 2023 was significantly higher in comparison with years 2020, 2021 and 2022 and significantly lower in comparison with 2018 (P-value=0.003). The outbreak in late 2023 can be explained by the seasonality of Mycoplasma pneumonia alone, which has shown outbreaks every 3-5 years, and it does not appear to be more severe than the previous one.

Keywords: Mycoplasma pneumoniae; Paediatric Pneumonia; Pneumonia; community acquired pneumonia; respiratory infections.

MeSH terms

  • Child
  • China / epidemiology
  • Humans
  • Mycoplasma pneumoniae* / genetics
  • Pneumonia, Mycoplasma* / epidemiology
  • Retrospective Studies
  • Spain / epidemiology

Grants and funding

This work was supported by consorcio Centro de Investigacion Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M-T), DIAVIR (Instituto de Salud Carlos III (ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III (ISCIII)/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud (ACIS) − Servicio Gallego de Salud (SERGAS)—Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS − Servicio Gallego de Salud (SERGAS) − XUNTA de Galicia; Spain) and Axencia Galega de Innovacion ´ (GAIN; IN607B 2020/08—XUNTA de Galicia; Spain); and ReSVinext (Instituto de Salud Carlos III (ISCIII)/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III (ISCIII)/PI19/01090/Cofinanciado FEDER), OMI-COVI-VAC (PI22/00406/Cofinanced European Regional Development Fund), Grupos de Referencia Competitiva (IIN607A2021/05) and Axencia Galega de Innovación (GAIN; IN845D 2020/23 − Xunta de Galicia; Spain).